New Treatment Option For Tough Breast Cancer Cases

New Treatment Option For Tough Breast Cancer Cases
Despite the advancment in techniques to address metastatic breast cancer, there are still very few effective treatment options. A recent phase 3 trial showed that palbociclib doubled the time to cancer recurrence in those suffering with hormone-receptor (HR+) positive metastatic breast cancer. The data was published in the New England Journal of Medicine journal and presented at the 2015 annual American Society of Clinical Oncology (ASCO). “These are women with advanced metastatic cancer whose disease was kept in check without the use of toxic and life-disrupting chemotherapy. This is a major advance for this population of women for which we had very few active options and are often treated with chemotherapy alone,” noted Massimo Cristofanilli, study's senior author and the Director of the Breast Care Center at Thomas Jefferson University. The PALOMA-3 study enrolled a total of 521 pre-/peri- and post-menopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor-negative (HER2-) advanced disease. These patients were not candidates for the HER2-blocking therapy herceptin since they had already relapsed on hormone therapy and were randomly assigned either palbociclib combined with fulvestrant, a drug that blocks the hormone receptor, or a placebo and fulvestrant. The study's primary endpoint was improvement i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.